OPTIMA is an Innovative Medicines Initiative (IMI) project that is using artificial intelligence (AI) to improve care for patients with lung, prostate and breast cancer, which ELF is proud to be a part of. OPTIMA would like patients and patient representatives to help them decide on the most important research priorities in lung cancer and breast cancer.
After consulting with healthcare professionals and patients, OPTIMA have created two surveys: one for lung cancer (20 minutes) and one for breast cancer (30 minutes). They want patients to tell them how important each research topic is. For example, one possible research area is to determine how many people worldwide get lung cancer. Patients can say if this is critically important, not important at all, or somewhere in between.
The surveys are available in English, French, German, Italian and Spanish.
The deadline to complete the surveys is Tuesday 31 October.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79